App-Quantinova.ai

Arginine metabolism is modulated by androgen signalling and prostate cancer progression

De-Xue Fu - American Association for Cancer Research (AACR) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Enzalutamide

Androgen receptor affects GLI activity by promoting transcriptionally active states of GLI upon androgen stimulation

Sarah Truong - American Association for Cancer Research (AACR) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Enzalutamide

Aberrant tumor metabolism enables GR takeover in enzalutamide-resistant prostate cancer

Jianneng Li - American Association for Cancer Research (AACR) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Enzalutamide

An oral Androgen Receptor PROTAC degrader for prostate cancer

Taavi K. Neklesa - American Association for Cancer Research (AACR) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Enzalutamide

Characterization of molecular mechanisms of cytoplasmic trafficking and nuclear translocation of AR splice variants ARv7

Eiman Mukhtar - American Association for Cancer Research (AACR) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Enzalutamide

Increased FGFRL1 expression is associated with prostate cancer progression

Lan Yu - American Association for Cancer Research (AACR) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Enzalutamide

Influence of 3D- cultured prostate cancer and stromal cells on drug response

Dominique N. Gales - American Association for Cancer Research (AACR) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Enzalutamide

Androgen insensitivity syndrome germline loss-of-function mutations in the androgen receptor that acquire somatic gain-of-function in prostate cancer

Philip A. Watson - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

Enzalutamide

Metformin enhances the anti-prostate cancer activity of abiraterone and enzalutamide

Yi Xie - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Prostate cancer

Enzalutamide

Synergistic in vitro activity of MOR209/ES414 in combination with enzalutamide

Toddy Sewell - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

Enzalutamide

A high-throughput PPI assay to quantify inhibition of androgen receptor variant 7 (AR-V7) binding to canonical AR full-length (AR-FL) binding partners

Jonathan Branch - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

N/A

Enzalutamide

Identifying a predictive biomarker for chemotherapy (taxane) in patients with metastatic castration resistance prostate cancer

Greg A. Rothchild - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

Enzalutamide

CPT1A-mediated lipid catabolism modulates growth, AR expression and hypoxia survival of prostate cancer

Isabel R. Schlaepfer - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Prostate cancer

Enzalutamide

Inhibition of hexose monophosphate pathway promotes castration resistant prostate cancer

Akash K. Kaushik - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

Enzalutamide

Tumor suppressing dual-action miRNA: Targeting Warburg effect and androgen receptor function in CRPC

Jey Sabith Ebron - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

Enzalutamide

Cytokine response of stromal cells to prostate cancer chemotherapeutics

Dominique Gales - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Prostate cancer

Enzalutamide

NTRK1/TRKA as a therapeutic target in castration resistant prostate cancer

James E. Korkola - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

Enzalutamide

Genistein-AR antagonist conjugate potently induce growth arrest in both androgen dependent and independent prostate cancer cell lines

Idris O. Raji - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

Enzalutamide

FOXA1, a novel regulator of neuroendocrine differentiation

Jung Kim - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

Enzalutamide

Identifying a novel mechanism underlying the enzalutamide and bicalutamide resistance in African-American prostate cancer patients

Arsheed Ganaie - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

Enzalutamide

Filters

999 Abstracts